The functional state of the gall bladder in patients with ischemic heart disease and obesity based on therapeutic correction due to rosuvastatin and mosapride.

Abstract

Cholesterosis is one of the most common diseases of the gallbladder. The frequency of the disease, according to surgeons, varies from 2.4 to 39.0%, according to pathologists – from 2.1 to 46.0%. According to the sonography of the gastrointestinal tract, the frequency of detection of cholesterosis in the gastroenterology clinic is 8.1-40.3%. Cholesterosis is often combined with cholesterol calculi, which gives reason for some authors to consider this disease as a pre-stage of gallstone disease. In some cases, cholesterosis is considered as one of the manifestations of the lipid distress syndrome, that is, a complex of diseases, the pathogenesis of which is based on hyperlipidemia and dyslipoproteinemia. In this regard, cholesterosis is often detected in patients with obesity, which is also a component of the lipid distress syndrome. Recognizing more than a century ago lipid infiltration of the gallbladder wall as the basis of future stones, unfortunately, did not change approaches to the treatment of cholesterosis, and advances in the diagnosis of this pathology did not contribute to significant strategic changes in treatment. Cholesterosis is one of the indications for cholecystectomy. Postcholecystectomy syndrome is a cause of disability. It can be associated with both technical errors of surgical intervention and functional disorders caused by the "loss" of functions of the gastrointestinal tract. Cholesterolemia and postcholecystectomy syndrome lead to a significant decrease in the quality of life of patients and even to disability. The aim of the study. To detect the effect of rosuvastatin and mosapride on the course of chronic cholecystitis and cholesterosis of the gallbladder in patients with coronary heart disease, cardiosclerosis and obesity, on the functional state of the endothelium, the intensity of oxidative and nitrosative stress, which are factors in the progression of the main and comorbid diseases.